Safety and Immune Response to a Multi-component Immune Based Therapy (MKC1106-PP) for Patients With Advanced Cancer.
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Ovarian|Melanoma|Renal|Prostate|Colorectal|Endometrial Carcinoma|Cervical Carcinoma|Testicular Cancer|Thyroid Cancer|Small Cell Lung Carcinoma|Mesothelioma|Breast Carcinoma|Esophageal Carcinoma|Gastric Cancer|Pancreatic Carcinoma|Neuroendocrine Cancer|Liver Cancer|Gallbladder Cancer|Biliary Tract Cancer|Anal Carcinoma|Bone Sarcomas|Soft Tissue Sarcomas|Carcinoma of Unknown Origin, Primary
Interventions: BIOLOGICAL: PSMA/PRAME|BIOLOGICAL: PSMA/PRAME
Sponsor: Mannkind Corporation